The second messenger molecule cyclic AMP dramatically modulates the apoptotic program in a wide variety of cells, accelerating apoptosis in some and delaying the rate of apoptosis in others. Human neutrophil apoptosis, a process that regulates the fate and numbers of these potentially histotoxic cells in inflammatory sites, is profoundly delayed by the cell-permeable analog of cyclic AMP, dibutyryl-cAMP. We have investigated the mechanisms underlying cyclic AMP-mediated delay of neutrophil apoptosis, and we show that cyclic AMP inhibits loss of mitochondrial potential occurring during constitutive neutrophil apoptosis. Furthermore, we demonstrate that cyclic AMP also suppresses caspase activation in these inflammatory cells. Despite increasing protein kinase A activity, this kinase is unlikely to mediate the effect of cyclic AMP on apoptosis because blockade of protein kinase A activation did not influence the survival effects of cyclic AMP. Further investigation of the signaling mechanism demonstrated that the delay of apoptosis is independent of phosphoinositide 3-kinase and MAPK activation. Our results suggest cyclic AMP delays neutrophil apoptosis via a novel, reversible, and transcriptionally independent mechanism. We show that proteasome activity in the neutrophil is vitally involved in this process, and we suggest that a balance of pro-apoptotic and anti-apoptotic proteins plays a key role in the powerful ability of cyclic AMP to delay neutrophil death.
The neutrophil is a terminally differentiated phagocytic cell that plays a key role in first line defense against invading bacteria. Neutrophils are rapidly recruited to inflamed sites in response to infection and, following phagocytosis of the invading organism, release a variety of toxic granule contents into the phagolysosome containing the engulfed microorganisms (1, 2) . The neutrophil normally has a short life span, and senescent neutrophils must be prevented from releasing their cytotoxic cell contents into the surrounding milieu because such liberation will lead to local tissue damage. To avoid this undesirable and inappropriate response, the neutrophil undergoes a regulated process of programmed cell death or apoptosis (3) (4) (5) , allowing shutdown of secretory capacity (6) and phagocytic removal of the intact effete cell by a mechanism that does not incite an inflammatory response (7) (8) (9) .
The execution of the apoptotic program generally involves the activation of a family of cysteine proteases, collectively referred to as the caspases, that are ultimately responsible for the structural dismantling of the cell (10, 11) . In addition, the mitochondria play a central role through their ability to integrate anti-apoptotic or pro-apoptotic signals from Bcl-2 family members with coordinated activation of downstream caspases and nucleases (12, 13) . In many cell types it has been documented that apoptosis is accompanied by an early dissipation of the mitochondrial transmembrane potential (⌬⌿m) with increased permeability of the outer mitochondrial membrane allowing release of apoptosis-inducing factors such as cytochrome c (12) (13) (14) . Neutrophils are thought to contain very few mitochondria, and it has not yet been fully established whether they have the capacity to play a functional role in regulation of neutrophil apoptosis (15, 16) .
Neutrophils undergo constitutive apoptosis during in vitro culture and exhibit the classic changes associated with apoptosis including cytoplasmic condensation, internucleosomal cleavage of DNA by endogenous endonucleases, and exposure of phosphatidylserine on the outer leaflet of the plasmalemma (3) . Although the apoptotic program in neutrophils is an intrinsic cell process, the rate of apoptosis can be altered dramatically by a number of agents (17) . In particular, we and others (18 -20) have shown that elevated levels of the second messenger cyclic AMP can prolong neutrophil longevity by delaying apoptosis.
The cyclic AMP-dependent signaling transduction pathway is a multienzyme cascade that regulates a diverse array of biological processes. Specific ligation of appropriate G-proteincoupled receptors followed by adenylate cyclase activation leads to the production of cyclic AMP. Cyclic AMP then binds to cytoplasmic protein kinase A, a tetrameric structure composed of two regulatory (R) and two catalytic (C) subunits, resulting in dissociation of the C subunits and subsequent phosphorylation of target proteins (21) . Although most components of this signaling cascade are well characterized, the molecular mechanisms underlying cyclic AMP-mediated modulation of apoptosis remain to be elucidated. The signaling mechanism(s) used by cyclic AMP to control these events is (are) likely to be complex and cell type-specific. For example, in contrast to the profound delay in the engagement of the apoptotic process in neutrophils (18 -20) , cyclic AMP elevation induces apoptosis in thymocytes (22) and leukemic cell lines (23, 24) . The signaling mechanism determining this ability to differentially influence apoptosis in diverse cell types remains to be elucidated.
In the present study we show that elevated cyclic AMP inhibits activation of caspase-3 and loss in mitochondrial potential (⌬⌿m) when neutrophils are aged in vitro, i.e. effects that appear to be associative rather that causative. Although we could demonstrate that cyclic AMP rapidly elevates endogenous PKA 1 activity in cultured neutrophils, blockade of PKA activation did not influence the observed delay in neutrophil apoptosis induced by cyclic AMP elevation. We also show that cyclic AMP elevation delays neutrophil apoptosis via a transcriptionally independent and reversible pathway, which does not require PI 3-kinase and MAPK activity. Together these data point to a novel mode of action for the major retardation of neutrophil apoptosis induced by cyclic AMP elevation.
EXPERIMENTAL PROCEDURES

Granulocyte Isolation and Culture
Neutrophils were purified from the peripheral blood of normal donors by dextran sedimentation (Sigma) followed by centrifugation on discontinuous Percoll TM (Amersham Pharmacia Biotech) gradients as described previously (25, 26) . Only neutrophil preparations with a purity of Ͼ98% were used. Cells were cultured in flat-bottomed Falcon flexible wells (Becton Dickinson, Oxford, UK) at 37°C in a 5% CO 2 atmosphere at a concentration of 5 ϫ 10 6 /ml in Iscove's modified Dulbecco's medium (Life Technologies, Inc.) supplemented with 100 units/ml penicillin/ streptomycin (Life Technologies, Inc.) and 10% (v/v) autologous serum. As an index of necrosis, cell membrane integrity was assessed by the ability of cells to exclude the vital dye trypan blue (Sigma). Under all experimental conditions, greater than 99% of the cells consistently excluded trypan blue.
Assessment of Granulocyte Apoptosis
Morphology-Cells were cyto-centrifuged, fixed in methanol, stained with Diff-Quik TM Gamidor Ltd. (Abingdon, Oxon, UK), and counted 1 The abbreviations used are: PKA, protein kinase A; Bt 2 cAMP, dibutyryl cyclic AMP; DMEM, Dulbecco's modified Eagle's medium; GM-CSF, granulocyte macrophage-colony-stimulating factor; JC-1 [5,5Ј,6,6Ј-tetrachloro-1,1Ј,3,3Ј-tetraethylbenzimidazocarbocyaniniodide; MAPK, mitogen-activated protein kinase; PI 3-kinase, phosphoinositide 3-kinase; PBS, phosphate-buffered saline; PGE 2 , prostaglandin E 2 ; FITC, fluorescein isothiocyanate.
FIG. 1.
Effect of cyclic AMP elevation on human neutrophil apoptosis. Human neutrophils (5 ϫ 10 6 /ml) were cultured at 37°C in Iscove's DMEM containing 10% autologous serum and treated with Bt 2 cAMP (dbcAMP) (0.2 mM) or PGE 2 (10 M). After 20 h, the cells were incubated with FITC-labeled recombinant human annexin V to determine phosphatidylserine expression. The cells were then assessed by flow cytometry on a FACSCalibur and analyzed on associated CellQuest software. Data from a minimum of 5000 cells were analyzed for each condition. All values represent mean Ϯ S.E. of n ϭ 5-8 experiments, each performed in duplicate where significant difference from control is represented by *, p Ͻ 0.001, and #, p Ͻ 0.05. Similar results were found by morphological assessment of apoptosis (data not shown).
cAMP Regulator Neutrophil Apoptosis via a Novel Pathwayusing oil immersion microscopy to determine the proportion of cells with distinctive apoptotic morphology (3, 26) . At least 500 cells were counted per slide with the observer blinded to the experimental conditions. The results were expressed as the mean percent apoptosis Ϯ S.E.
Annexin V Binding-A separate and independent assessment of apoptosis was performed by flow cytometry using annexin V binding (annexin V-FLUOS, Roche Molecular Biochemicals) to measure phosphatidylserine exposure on the surface of apoptotic cells. A working solution of annexin V-FLUOS was made from stock annexin V-FLUOS (0.1 g/l) diluted 1:3000 in Hanks' balanced salt solution (Sigma) supplemented with 2.5 mM CaCl 2 . Neutrophils (20 l of 5 ϫ 10 6 /ml) were added to 200 l of the working solution of annexin V-FLUOS before being assessed by flow cytometry on a FACSCalibur (Becton Dickinson, Oxford, UK) and analyzed on associated CellQuest (Becton Dickinson) software. All experiments were performed at least three times unless otherwise indicated.
Measurement of PKA Activity
PKA activity was measured using Promega's SignaTECT TM cAMPdependent Protein Kinase (PKA) Assay System, which utilizes biotinylated Kemptide (LRRASLG), a peptide substrate derived from the in vivo substrate pyruvate kinase. Neutrophils (5 ϫ 10 6 cells) were preincubated with control buffer or 10 M H89 (Calbiochem) for 1 h in PBS with Ca 2ϩ /Mg 2ϩ (or for 19 h in DMEM Iscove's with 10% autologous serum) at 37°C before being stimulated with 0.2 mM Bt 2 cAMP or 1 M PGE 2 (both from Sigma) for 30 min at 37°C. Following one wash in ice-cold PBS, neutrophils were resuspended in 0.5 ml of cold extraction buffer (25 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM ␤-mercaptoethanol, 1 g/ml leupeptin, 1 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 1% Triton X-100 (Sigma)). The lysates were centrifuged (5 min at 4°C; 14,000 ϫ g) and the supernatants retained. The PKA reaction mixture consisting of 5 l of 5ϫ PKA Assay Buffer, 5 l of cyclic AMP (0.025 mM), 5 l of PKA-biotinylated peptide substrate (0.5 mM), 5 l of [␥- 33 P]ATP mixture (5 l of 0.5 mM ATP and 0.05 l of [␥- 33 P]ATP (3,000 Ci/mmol) 10 Ci/l) was mixed gently and preincubated at 30°C for 5 min (Promega, Southampton, UK). A control reaction without substrate was performed to determine background counts. The PKA activity reaction was initiated by adding 5 l of the lysates to the reactants and incubated at 30°C for 5 min. The reaction was terminated by adding 12.5 l of Termination Buffer to each sample (Promega, Southampton, UK). Aliquots (10 l) from each terminated reaction sample were spotted onto prenumbered SAM 2TM membrane squares (Promega, Southampton, UK). The SAM 2TM membrane squares containing the spotted samples were then washed 1 time for 30 s with 200 ml of 2 M NaCl (Sigma) followed by 3 washes for 2 min with 200 ml of 2 M NaCl and then 4 washes for 2 min with 200 ml of 2 M NaCl in 1% H 3 PO 4 . Finally the Membrane squares were quickly washed in deionized water before being allowed to dry. PKA activity was measured by scintillation counting.
Measurement of Mitochondrial Dissipation
Changes in mitochondrial potential were measured in neutrophils following stimulation using JC-1 (5,5Ј,6,6Ј-tetrachloro-1,1Ј,3,3Ј-tetraethylbenzimidazocarbocyaniniodide (Molecular Probes), a cationic dye that exhibits potential dependent accumulation in mitochondria indicated by a fluorescence emission shift from green (525 nm) to red (590 nm) (27) . Mitochondrial depolarization is therefore indicated by a decrease in the red/green fluorescence intensity ratio. JC-1 (10 g/ml) was diluted in PBS from stock JC1 (5 mg/ml in Me 2 SO) and added to neutrophils (1 ϫ 10 6 /ml) for 10 min at 37°C. Neutrophil mitochondria labeled with JC-1 were examined by confocal fluorescent microscopy together with TO-PRO-3 (1 M) (Molecular Probes) (28) to assess neutrophils with necrotic morphology. Alternatively, neutrophils labeled with JC-1 were assessed by flow cytometric analysis using FACSCalibur (Becton Dickinson, Oxford, UK) and analyzed on associated CellQuest (Becton Dickinson) software. Non-apoptotic neutrophils were removed using immunomagnetic separation with sheep anti-mouse IgG-Dynabeads (Dynabeads M-450, Dynal, Mersyside, UK) coated with the murine anti-neutrophil antibody 3G8 (anti-CD16; a gift from Dr. J. Unkeless, Mount Sinai Medical School, New York). Cells were mixed with washed antibody-coated magnetic beads on a rotary mixer at 4°C for 20 min, and the beads removed magnetically by two 3-min stationary magnetic contacts (Dynal Magnetic Particle Concentrator, MPC-1) to yield an apoptotic neutrophil preparation. After purification, the apoptotic neutrophils were labeled with JC-1 as described previously.
Western Blotting
Human neutrophils (5 ϫ 10 6 /ml) were cultured with or without Bt 2 cAMP (0.2 mM) at 37°C for various time points as detailed under "Results." Cytoplasmic extracts were then prepared from equivalent numbers of cells (10 ϫ 10 6 cells). To minimize problems with proteolysis, lysates were prepared using methods normally used for electrophoretic mobility shift assay preparations (26, 29) with the addition of 1 mM phenylmethylsulfonyl fluoride. Samples were loaded onto a 12.5%
FIG. 2. Time course for the effect of Bt 2 cAMP (dbcAMP) on caspase-3 expression during human neutrophil apoptosis.
A, Western blot of cytoplasmic extracts from neutrophils treated with control buffer or Bt 2 cAMP (0.2 mM) for the time points indicated. Cell lysates were prepared and immunoblotted as described under "Experimental Procedures." Lysates were prepared from equivalent numbers of cells and subjected to SDS-polyacrylamide gel electrophoresis/immunoblot analysis using a rabbit polyclonal antibody specific for caspase-3. The caspase-3 antibody recognizes both the 32-kDa pro-caspase-3 and the 17-kDa subunit of active caspase-3. The 17-kDa caspase-3 cleavage product is faintly visible in control (con) lysates at 8 h becoming more apparent by 20 h. There appears to be less active caspase-3 in Bt 2 cAMP (dbcAMP)-treated cell lysates compared with control cell lysates. The gel is representative of three experiments. B, human neutrophils were treated with or without Bt 2 cAMP (0.2 mM) for the time points indicated under equivalent culture conditions as the cells used for caspase-3 expression assessment above. Cells were assessed for apoptosis by measurement of phosphatidylserine expression using annexin V FITC. Data from a minimum of 5000 cels were analyzed for each condition. All values represent mean Ϯ S.E. of n ϭ 3 experiments, each performed in duplicate.
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Tris-HCl polyacrylamide mini-gel under reducing conditions and transferred to nitrocellulose membrane (Amersham Pharmacia Biotech) at 60 V for 1 h before overnight incubation at 4°C with an antibody specific to caspase-3 (catalog number 65906E, PharMingen). After washing, blots were incubated with donkey anti-rabbit horseradish peroxidase conjugate (Amersham Pharmacia Biotech) diluted 1:2000 and developed using a commercial chemiluminescence detection system (ECL, Amersham Pharmacia Biotech).
Further Materials
Further specific materials were obtained as follows: (R p )-8-BrcAMPS, PD98059, SB203580, and cycloheximide (Calbiochem); lactacystin and epoxomicin (Affiniti, Mamhead, UK); and LY294002 (New England Biolabs, Hertfordshire, UK).
Statistical Analysis
Statistical analysis was performed using the Student's t test or by analysis of variance with comparisons between groups made using the Newman-Keuls procedure. Differences were considered significant when p Ͻ 0.05.
RESULTS
Elevation of Cyclic AMP Delays Neutrophil Apoptosis-To
examine the effects of cyclic AMP on apoptosis induction, neutrophils were exposed to Bt 2 cAMP, a membrane-permeant cyclic AMP analog and the receptor-directed stimulus PGE 2 , for 20 h. Both Bt 2 cAMP and PGE 2 delay neutrophil apoptosis, determined by standard morphological criteria (data not FIG. 3 . A, determination if neutrophils contain mitochondria. Human neutrophils (1 ϫ 10 6 /ml) were cultured at 37°C in Iscove's DMEM containing 10% autologous serum. Neutrophils were labeled with JC-1, a mitochondrial specific dye, and examined by confocal fluorescent microscopy as described under "Experimental Procedures." Bottom panels show TO-PRO-3 staining for neutrophils with necrotic morphology (blue). B, effect of Bt 2 cAMP (dbcAMP) on dissipation of mitochondrial transmembrane potential during human neutrophil apoptosis. Human neutrophils (5 ϫ 10 6 /ml) were cultured for 20 h at 37°C in Iscove's DMEM containing 10% autologous serum with or without Bt 2 cAMP (dbcAMP) (0.2 mM). Cells were then labeled with the mitochondrial specific dye JC-1 as described under "Experimental Procedures" before flow cytometric analysis of mitochondrial membrane potential using a FACSCalibur and associated CellQuest software. Non-apoptotic neutrophils (bottom right panel) were removed by anti-CD16 immunodepletion before the remaining cells were labeled with JC-1. Shown is one representative experiment.
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shown) and annexin V binding (Fig. 1) . It is interesting to note that maximal concentrations of Bt 2 cAMP (0.2 mM) were more effective at delaying neutrophil apoptosis compared with maximal concentrations of PGE 2 (10 M) (Fig. 1) .
Bt 2 cAMP Inhibits Caspase Activation but Is Unlikely to Act Directly as an Inhibitor of Caspases-It is widely believed that
caspases act as the main executioners of apoptosis, with their activation resulting in chromatin condensation and DNA fragmentation. Whether cyclic AMP delays constitutive neutrophil apoptosis by directly suppressing caspase activation in neutrophils has not been examined. Therefore, we investigated the effect of cyclic AMP on activation of caspase-3 during constitutive apoptosis by immunoblotting. Neutrophils were found to express active caspase-3 (17 kDa) which closely correlates with the exposure of phosphatidylserine during constitutive neutrophil apoptosis (Fig. 2, A and B) . By 20 h there is significant caspase-3 activity (17 kDa) which can be inhibited by Bt 2 cAMP. The appearance of some caspase-3 activity in the presence of Bt 2 cAMP at 20 h probably reflects the presence of some apoptotic cells in the population (Fig. 2B) . 2 cAMP-In many cell models, apoptosis is accompanied by an early dissipation of the mitochondrial transmembrane potential (⌬⌿m). Previous data (16) have indicated that neutrophils do not respire, and it was thought unlikely that they contained mitochondria. By using confocal microscopy and flow cytometry, we have been able to demonstrate that neutrophils do contain mitochondria (orange), which during overnight culture exhibit loss of mitochondrial potential as indicated by an increase in green fluorescence (Fig. 3A) . Our studies also reveal that Bt 2 cAMP inhibits changes in mitochondrial potential occurring during constitutive neutrophil apoptosis (Fig.  3B) . As the number of cells showing loss of mitochondrial potential appeared to correlate with the number of apoptotic cells measured by annexin V positivity in previous experiments (Fig. 1) , we examined directly if loss in mitochondrial potential occurred in those neutrophils undergoing apoptosis. It is well established that neutrophils lose cell surface expression of CD16 during the process of apoptosis (30) . Immunodepletion of non-apoptotic neutrophils using anti-CD16 magnetic beads demonstrated apoptotic neutrophils were indeed positive for loss of mitochondrial potential (Fig. 3B) indicating that dissipation of mitochondrial membrane potential occurs in neutrophils undergoing programmed cell death.
Apoptosis in Neutrophils Is Accompanied by Dissipation of Mitochondrial Transmembrane Potential That Can Be Inhibited by Bt
It has been shown previously (31) 2 mM) . After a further 20 h in culture, the cells were incubated with FITC-labeled recombinant human annexin V to determine phosphatidylserine expression. The cells were then analyzed by flow cytometry using a FACSCalibur and associated CellQuest software. Data from a minimum of 5000 cells were analyzed for each condition. All values represent mean Ϯ S.E. of n ϭ 3 experiments, each performed in duplicate. Similar results were found when cells were assessed for apoptosis by morphological examination (data not shown). C, human neutrophils (5 ϫ 10 6 /ml) cultured in Iscove's DMEM containing 10% autologous serum at 37°C were preincubated with 10 M H89 for 19 h before being stimulated with PGE 2 (1 M) for 1 h at 37°C. PKA activity was measured as described under "Experimental Procedures." All values represent mean Ϯ S.E. of n ϭ 5 experiments where significant difference from PGE 2 alone is represented by **, p Ͻ 0.01.
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mitochondrial respiratory chain do not affect constitutive neutrophil apoptosis, raising the question of the source of their ⌬⌿m. It may be the case that the neutrophil maintains a transmembrane gradient by a functional F 1 ,F 0 -ATPase; however, this needs to be investigated in more detail.
Cyclic AMP Elevation Stimulates PKA Activation in Neutrophils, an Effect That Is Blocked by Pharmacological Inhibitors-
To elucidate further the mechanism by which cyclic AMP regulates neutrophil apoptosis, we examined its downstream signaling pathway. The effects of cyclic AMP are thought to be mediated through binding of cyclic AMP to the intracellular kinase, PKA. This leads to the dissociation of PKA into regulatory and catalytic subunits, which can consequently lead to phosphorylation events of proteins such as the cyclic AMPresponse element-binding protein (21) . To explore whether cyclic AMP suppresses apoptosis and apoptotic signaling via activating the PKA pathway in neutrophils, we examined the effects of Bt 2 cAMP on endogenous PKA activation (Fig. 4) . We found rapid activation of PKA when cells were treated with both Bt 2 cAMP and PGE 2. Furthermore, the activation of PKA upon stimulation of neutrophils with cyclic AMP elevators could be blocked by the pharmacological PKA inhibitor H89 (32) (Fig. 4) .
Activation of the PKA Pathway Does Not Account for Cyclic
AMP-mediated Retardation of Apoptosis-To investigate whether PKA activation by cyclic AMP was necessary for cyclic AMP-mediated delay of apoptosis, neutrophils were incubated with the PKA inhibitor H89 before being stimulated with Bt 2 cAMP and assessed for apoptosis. Surprisingly, whereas pre-treatment with H89 prevented activation of PKA, it did not prevent the inhibition of apoptosis by Bt 2 cAMP (Fig. 5A) . Additionally, the highly specific inhibitor of PKA, (R p )-8-BrcAMPS (100 M), also failed to block Bt 2 cAMP inhibition of neutrophil apoptosis (Fig. 5B ). This suggests that cyclic AMP elevation stimulates PKA activity but PKA does not play a major role in the anti-apoptotic effect of cyclic AMP elevation in neutrophils.
The ability of H89 to block PKA activity, as shown by direct measurement of kinase activity, suggests a lack of involvement of PKA in the anti-apoptotic effect of cyclic AMP in neutrophils. Most importantly, we investigated whether H89 could block PKA activity for the full overnight culture period and under identical culture conditions that we use for our apoptosis assay. Neutrophils were therefore cultured in serum-supplemented Iscove's DMEM for 19 h in the presence or absence of H89 before stimulation with PGE 2 for 1 h. PKA activity was then measured as described under "Experimental Procedures." We found that H89 could still block PGE 2 -stimulated PKA activity 
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at 20 h (Fig. 5C ). This is very important because it demonstrates that the inability of H89 to reverse cyclic AMP-mediated delay of neutrophil apoptosis is not due to degradation of H89 during the overnight culture period. Furthermore, it also demonstrates that H89 is not inactivated by autologous serum that is used in our apoptosis assay.
Activation of Akt/PI 3-Kinase or Mitogen-activated Kinase Pathways Does Not Account for the Bt 2 cAMP-mediated Delay of
Neutrophil Apoptosis-The phosphoinositide 3-kinase/Akt pathway plays an essential role in cell survival in various cell types (33) and may be involved in the cyclic AMP-signaling cascade. For example, it has been reported that cyclic AMP requires PI 3-kinase activation for DNA synthesis induced by insulin-like growth factor I in FRTL-5 cells (34) and is involved in the ability of cyclic AMP to attenuate chemoattractantinduced respiratory burst in neutrophils (35) . Therefore, we examined whether PI 3-kinase is involved in the signaling pathway mediating the protective effect of cyclic AMP on neutrophil survival. Cells were preincubated with the specific PI 3-kinase inhibitor LY294002 (36) prior to exposing them to Bt 2 cAMP or GM-CSF (Fig. 6) . We found that the PI 3-kinase inhibitor suppressed GM-CSF-mediated delay of neutrophil apoptosis, which has been reported previously (37) , yet had no effect on suppression of apoptosis by Bt 2 cAMP.
We also investigated whether cyclic AMP could be acting through the MAPK signaling pathway to delay neutrophil apoptosis. Activation of extracellular signal-regulated kinase has been implicated in a number of systems to contribute as a negative regulator of apoptosis (38, 39) . Elevation of cyclic AMP levels is also known to either inhibit or activate MAPK in a cell typeand stimulus-specific manner (40, 41) . The protective effect of cAMP-elevating agents does not appear to act through the MAPK pathway in our system because the p42/p44 MAPK kinase inhibitor PD98059 had no effect on the anti-apoptotic functions of cyclic AMP in neutrophils, yet reversed the anti-apoptotic functions of GM-CSF treatment in neutrophils (Fig. 6) . Similarly the p38 MAPK inhibitor SB203580 (42) did not reverse Bt 2 cAMPmediated delay of neutrophil apoptosis (data not shown). 6 /ml) cultured in Iscove's DMEM containing 10% autologous serum at 37°C were treated with or without Bt 2 cAMP (dbcAMP) (0.2 mM) for the time points indicated before the cells were washed 2 times in PBS to remove Bt 2 cAMP and returned to culture. Cells were cultured in Iscove's DMEM containing 10% autologous serum until 20 h when the cells were resuspended and incubated with FITC-labeled recombinant human annexin V to determine phosphatidylserine expression. The cells were then assessed by flow cytometry on a FACSCalibur and analyzed on associated CellQuest software. Data from a minimum of 5000 cells were analyzed for each condition. All values represent mean Ϯ S.E. of n ϭ 3 experiments, each performed in duplicate. B, human neutrophils (5 ϫ 10 6 /ml) cultured in Iscove's DMEM containing 10% autologous serum at 37°C for the time points indicated before addition of Bt 2 cAMP (0.2 mM). At 20 h, cells were resuspended and incubated with FITC-labeled recombinant human annexin V to determine phosphatidylserine expression. The cells were then assessed by flow cytometry on a FACSCalibur and analyzed on associated CellQuest software. Data from a minimum of 5000 cells were analyzed for each condition. All values represent mean Ϯ S.E. of n ϭ 3 experiments, each performed in duplicate.
cAMP Regulator Neutrophil Apoptosis via a Novel PathwayRetardation of Neutrophil Apoptosis by Bt 2 cAMP Does Not
Require New Protein Synthesis-Our results suggest Bt 2 cAMP suppresses neutrophil apoptosis via a previously uncharacterized signaling mechanism. We therefore determined whether Bt 2 cAMP stimulated a novel signaling pathway that would require transcriptional activation to suppress neutrophil apoptosis.
To block protein synthesis cycloheximide was titrated to low concentrations to minimize the induction of neutrophil apoptosis that has been reported by this compound (43) . Apoptosis was assessed by morphology and annexin V binding following overnight culture of neutrophils with Bt 2 cAMP and cycloheximide (Fig. 7) . Cycloheximide failed to reverse the suppression of apoptosis by cyclic AMP. It did however block glucocorticoidmediated suppression of neutrophil apoptosis at these concentrations (Ref. 44 and data not shown), suggesting that gene transcription is not necessary for the suppression of neutrophil apoptosis by Bt 2 cAMP.
We next examined the possibility that Bt 2 cAMP might activate a rapid and reversible signaling pathway rather than stimulate new protein synthesis, which would occur over several hours. Cells were cultured in the presence of Bt 2 cAMP for the time points indicated before Bt 2 cAMP was removed from culture by gently washing in PBS and then returned to normal culture conditions. Bt 2 cAMP was required to be continually present in culture to suppress neutrophil apoptosis (Fig. 8A) . However, Bt 2 cAMP rescued neutrophils from apoptosis when added at later time points (Fig. 8B) . We are investigating whether the effects of cyclic AMP occur when the rate of apoptosis is high (between 8 and 20 h). However, during constitutive apoptosis, cells at different stages of the apoptotic program are present in the population at any one time point. We are currently investigating whether synchronous apoptosis triggered by Fas ligation, tumor necrosis factor-␣ (26), or temperature shift (15) can be modulated by cyclic AMP. Taken together, our results suggest that Bt 2 cAMP exerts a powerful direct signaling mechanism, independent of new protein synthesis, to suppress neutrophil apoptosis, and this suppression is rapidly lost when Bt 2 cAMP is removed from culture.
Proteasome Inhibitors Are Able to Reverse Retardation of Neutrophil Apoptosis by Bt 2 cAMP-The ubiquitin/proteasome system plays an important role in the degradation of cellular proteins that regulate various cellular processes, including apoptosis. The observations above reveal Bt 2 cAMP delays neutrophil apoptosis independently of new protein synthesis, suggesting that Bt 2 cAMP is unlikely to stimulate the production of a survival protein. Thus we examined whether alternatively Bt 2 cAMP was accelerating the degradation or modification of pro-death proteins within the neutrophil to increase survival. Neutrophils were co-incubated with Bt 2 cAMP and the irreversible proteasome inhibitors lactacystin (10 M) (45) and epoxomicin (10 M) (46) for 20 h (Fig. 9, A and B) . Both proteasome inhibitors eliminated the delay of neutrophil apoptosis induced by Bt 2 cAMP.
DISCUSSION
Human neutrophils undergo apoptosis, a process that is centrally important in the resolution of inflammation. It has been shown previously that cyclic AMP is an important regulator of neutrophil apoptosis (18 -20) , yet little is known of the signaling mechanism by which by cyclic AMP controls neutrophil cell death. The studies herein have established that cyclic AMP acts upstream of caspase-3 activation to inhibit the apoptotic pathway in neutrophils. For the first time, it was also demonstrated that neutrophils contain a small but significant number of mitochondria, which exhibit a loss of membrane potential during constitutive apoptosis, which can be delayed by cyclic AMP elevation. We are currently investigating whether loss of mitochondrial membrane potential occurs before other indices of apoptosis in neutrophils, such as phosphatidylserine exposure and nuclear condensation. This would help ascertain whether loss of mitochondrial potential during neutrophil apoptosis, shown to trigger apoptosis in other cell types, has a similar function in neutrophils and whether Bt 2 cAMP can directly affect loss of mitochondrial potential to delay neutrophil apoptosis.
It has been suggested that PKA plays an important role in cyclic AMP-mediated delay of neutrophil apoptosis (18 -20) . It is known that cyclic AMP analogs, which selectively activate type I PKA, attenuate neutrophil apoptosis, compared with analogs that preferentially activate type II PKA suggesting that that type I PKA is necessary and sufficient to mediate the cyclic AMP-induced delay in human neutrophil apoptosis (19) . We suggest, alternatively, that PKA activation by cyclic AMP is not responsible for the major apoptosis-retarding influences of cyclic AMP in neutrophils. Indeed, we have demonstrated directly that cyclic AMP elevation in neutrophils stimulates an increase in PKA activity, which is blocked by pharmacological inhibitors. Importantly, however, blockade of PKA was not sufficient to reverse the anti-apoptotic effect of cyclic AMP, implying that this molecule has little or no role in the cyclic AMP signaling pathway responsible for delay of neutrophil apoptosis.
Previous publications (18, 19) have implicated a role for PKA in cyclic AMP regulation of neutrophil apoptosis using concentrations of H89 greater than 10 M. The specificity of H89 at these concentrations is questionable, and it has been published (47) that H89 may inhibit several other kinases, some with potency similar to or greater than that for PKA. We propose that failure to directly measure PKA activity together with the use of high and possibly nonspecific concentrations of H89 could have led to misinterpretation of previous data. We have demonstrated that 10 M H89 is sufficient to block PKA activity for extended culture periods and is active in the presence of autologous serum. The failure therefore of both H89 and (R p )-8-Br-cAMPS, a highly specific inhibitor of PKA, to reverse cyclic AMP-mediated delay of neutrophil apoptosis points to a novel signaling pathway used by cyclic AMP to inhibit neutrophil apoptosis, which is independent of PKA activation.
There have been a few studies reporting PKA-independent effects of cyclic AMP; however, little has been elucidated of the alternative signaling pathways downstream of cyclic AMP. Pharmacological blockade of the MAPK and PI 3-kinase signaling cascades in this study suggest that neither of these signaling pathways are likely to be important in the cyclic AMPmediated delay of neutrophil apoptosis. There has been interest in the discovery that cyclic AMP can bind specifically to and activate small guanine nucleotide exchange factors which, when bound by cyclic AMP, activate the small Ras-like GTPase, Rap1 (48, 49) . The biological function of Rap1 is still unclear, but it has been proposed that activation of this small GTPase may feed into MAPK signaling pathways (50) . As an approach to establishing if Rap1 has a role in cyclic AMPmediated delay of neutrophil apoptosis, we have blocked Rap1 activity using the Clostridium sordellii lethal toxin, which has been reported to inhibit specifically the small GTPases Rap1, Ras, and Rac (51) . Furthermore, we have tested GGTI-286, a geranylgeranyltransferase inhibitor, which blocks geranylgeranylation required by Rap1 to achieve its mature, biologically active form (52) . Thus our preliminary experiments suggest that Rap1 is not involved in cyclic AMP-mediated delay of neutrophil apoptosis (data not shown): however, this area of research is still under investigation. Our studies are in accord with a very recent publication that demonstrates that cyclic AMP-dependent inhibition of interleukin-5 from human T lymphocytes is not mediated by PKA or by the Rap1 signaling pathway (53) .
Regulation of neutrophil apoptosis is thought to depend on the balance between pro-apoptotic and anti-apoptotic death factors expressed in the cell (17, 54) . Neutrophils contain death regulator proteins, including Bax and Bad, and also express some members of the anti-apoptotic family such as Mcl-1 and Bcl-x L but not Bcl-2 (17, 54) . It has been proposed that neutrophil longevity may be prolonged by the synthesis of anti-apoptotic proteins such as Mcl-1 (55) . However, it is unlikely that cyclic AMP effects are mediated by such a mechanism in the retardation of neutrophil apoptosis since we have demonstrated that cyclic AMP-mediated delay of neutrophil apoptosis does not require gene transcription. Furthermore, "wash out" experiments have revealed that retardation of neutrophil apoptosis is rapidly lost when Bt 2 cAMP is removed from culture, even after incubation periods that should permit new protein synthesis.
Together, these data suggest a mechanism whereby cyclic AMP does not stimulate production of a survival protein but may alternatively induce post-transitional modifications in the neutrophil to promote survival. One potential mechanism for cyclic AMP-mediated retardation of neutrophil apoptosis may involve cyclic AMP specifically targeting a death protein(s) to the proteasome for degradation. We have demonstrated that blockade of proteasome activity results in a dramatic loss of the pro-survival effect of cyclic AMP. We speculate that cyclic AMP may be involved in the post-translational modification of a death protein, which targets the neutrophil proteasome. If cyclic AMP stimulation is removed or proteasome activity is blocked, then the accumulation of a death protein(s) would be predicted to permit the constitutive death pathway of neutrophils to be reconstituted. Further characterization of proteasome activity in this signaling pathway and possible death protein targets of cyclic AMP are currently under investigation.
In conclusion, cyclic AMP delays neutrophil apoptosis via a novel, reversible, and transcriptionally independent mechanism. Our results contest the dogma that cyclic AMP exerts is physiological functions almost entirely through activation of PKA, and we are currently investigating the involvement of novel downstream signaling pathways in cyclic AMP regulation of neutrophil cell death.
